Product
MT-0169
1 clinical trial
1 indication
Clinical trial
A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2023-12-13